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Abstract
Background: We have previously demonstrated that the chronic intervention in the cholinergic system by donepezil, an
acetylcholinesterase inhibitor, plays a beneficial role in suppressing long-term cardiac remodeling after myocardial
infarction (MI). In comparison with such a chronic effect, however, the acute effect of donepezil during an acute phase of MI
remains unclear. Noticing recent findings of a cholinergic mechanism for anti-inflammatory actions, we tested the
hypothesis that donepezil attenuates an acute inflammatory tissue injury following MI.
Methods and Results: In isolated and activated macrophages, donepezil significantly reduced intra- and extracellular matrix
metalloproteinase-9 (MMP-9). In mice with MI, despite the comparable values of heart rate and blood pressure, the
donepezil-treated group showed a significantly lower incidence of cardiac rupture than the untreated group during the
acute phase of MI. Immunohistochemistry revealed that MMP-9 was localized at the infarct area where a large number of
inflammatory cells including macrophages infiltrated, and the expression and the enzymatic activity of MMP-9 at the left
ventricular infarct area was significantly reduced in the donepezil-treated group.
Conclusion: The present study suggests that donepezil inhibits the MMP-9-related acute inflammatory tissue injury in the
infarcted myocardium, thereby reduces the risk of left ventricular free wall rupture during the acute phase of MI.
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Introduction
In 2000, K. J. Tracey and coworkers reported the role of
efferent vagus nerve signaling in modulating inflammation [1].
The electrical stimulation of the efferent vagus nerve releases
acetylcholine (ACh), a principal vagal neurotransmitter, and
ACh seems to attenuate systemic inflammatory responses by
inhibiting the production of pro-inflammatory cytokines from
activated macrophages and other immune cells. The ‘cholin-
ergic’ anti-inflammatory pathway would provide a new thera-
peutic modality for the clinical treatment of inflammatory
disorders [2].
We have reported another aspect of the beneficial effect of the
vagal nerve stimulation [3]. Chronic vagal nerve stimulation with
an implantable stimulator prevented the cardiac pumping
dysfunction and improved long-term survival in rats with chronic
heart failure after large myocardial infarction (MI). Although the
precise mechanisms of the protective effect of the vagal nerve
stimulation on cardiomyocytes have not yet been fully elucidated,
our previous studies have clearly demonstrated that the antiar-
rhythmogenic effects are mediated by preservation of the gap-
junctional protein, connexin 43, and the antiapoptotic effects are
derived from the PI3K/Akt/HIF-1a signaling pathway in
cardiomyocytes, both of which are proposed to be involved in
the mechanism of the cardioprotective effect of the vagal nerve
stimulation [4,5]. The therapeutic modality of the vagal nerve
stimulation has been recently applied for patients with heart failure
in a clinical trial without significant side effects [6–8], however, it
might have disadvantages because it is an invasive procedure
suffering a surgical strain to the patients. Since a novel and a more
effective therapeutic strategy against heart failure is mandatory, we
have studied the effect of an acetylcholinesterase inhibitor,
donepezil, on heart failure expecting the cardioprotective effect.
Donepezil is a therapeutic acetylcholinesterase inhibitor for
treatment of Alzheimer’s disease, a neurodegenerative disorder
characterized with a depletion of nicotinic ACh receptors and a
loss of cholinergic neurons [9]. A number of studies using animal
models have demonstrated that donepezil possesses the neuropro-
tective activity in vivo [10], and in vitro [11,12]. In addition, it has
been recently demonstrated that the administration of donepezil
reproduced the effect of the vagal nerve stimulation. For example,
donepezil has been shown to 1) prevent cardiac remodeling with
enhancing vagal activity in a rat chronic MI model [13], 2)
improve survival by preventing pumping failure in a mouse
volume overload model [14] and 3) up-regulate angiogenesis by
modulating angiogenesis-responsible machinery of endothelial
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donepezil possesses not only neuroprotective but cardioprotective
effects. In comparison with such chronic effects, however, the
acute effect of donepezil during an acute phase of MI remains
unclear.
Even though surgical techniques for ischemic heart failure have
been improved, left ventricular free wall rupture has been still one
of the most lethal complications occurring in up to 10% patients
with acute MI [16]. Clinical and pathological studies in humans
have reported that the mean interval between diagnosis of acute
MI and the appearance of left ventricular free wall rupture ranged
from 1 to 5 days after MI [17–21]. Approximately 60% of the left
ventricular free wall rupture occurred within 5 days postinfarction
[22]. A large number of studies have shown that a severe
inflammatory cell infiltration following acute MI markedly
activates various matrix metalloproteinases (MMPs) which rapidly
degrade the fibrillar collagen network and weaken the tensile
strength of the infarcted myocardium, resulted in wall rupture
[23,24]. Therefore, the suppression of MMPs during an acute
phase of MI is a potential target for the therapeutic intervention
[25–30].
In the present study, noticing recent findings of a cholinergic
mechanism for anti-inflammatory actions, the effect of donepezil
on inflammatory response and cardiac rupture during the acute
phase of MI was investigated. Present results showed that
donepezil inhibits MMP-9, a member of the MMP family, in
macrophages and attenuates infiltration of inflammatory cells into
the infarcted myocardium, thereby reduces the risk of cardiac
rupture during the acute phase of MI, suggesting that donepezil
can be a new potential candidate for a clinically useful drug for
heart failure therapy.
Materials and Methods
Animals
Male C57BL/6 mice (Japan SLC inc., Hamamatsu, Japan) aged
between 9 and 11 weeks and weighed 20–25 g were used. All
animal procedures were performed in strict accordance with
guidelines of the Physiological Society of Japan and were approved
by the Animal Research Committee of Kochi Medical School
(Permit Number: C-00036).
Macrophage isolation and sample preparation
From mice euthanized with ether inhalation, peritoneal
macrophages were obtained by washing out the abdominal cavity
with ice-cold phosphate buffered saline (PBS). Cells were collected
by centrifugation, resuspended in RPMI 1640 medium (Sigma-
Aldrich Japan, Tokyo, Japan) containing 10% fetal bovine serum
(Tissue Culture Biologicals, CA, USA), and seeded at a
concentration of more than 3610
6 cells/well of a 12-well plastic
dish. After incubation at 37uC for 2 hrs, non-adherent cells were
flushed away and adhered cells were further incubated at 37uC for
18 hrs in RPMI 1640 medium with or without donepezil, an
acetylcholinesterase inhibitor, provided by Eisai Co., Ltd. (Tokyo,
Japan) at a concentration of 100 mM. Three hours after the
addition of lipopolysaccaride (LPS, Sigma-Aldrich Japan, Tokyo,
Japan) at a concentration of 10 ng/ml, culture medium was
collected from each well and mixed with same amount of twice
concentrated sample buffer (125 mM Tris-HCl (pH 6.8), 20%
glycerol, 4% sodium dodecyl sulfate (SDS), 10% 2-mercaptoeth-
anol and 0.1% bromophenol blue), or the sample buffer was
directly added to the adhered cells. Protein samples were boiled
with a THERMO BLOCK ND-M11 (Nissin, Tokyo, Japan) for
5 min before electrophoresis.
Immunocytochemistry
Isolated macrophages seeded onto a glass-bottom dish
(Matsunami Glass Industry, Ltd., Tokyo, Japan) were stimulated
by LPS with or without donepezil pretreatment as described
above. Cells fixed with 4% paraformaldehyde phosphate buffer
solution for 30 min at room temperature were permeabilized
with 1% buffered triton X-100 for 15 min, and blocked with 10%
goat serum in tris buffered saline with 0.2% Tween 20 (TBS-T)
for 30 min. Thereafter, cells were incubated with a rabbit
polyclonal anti mouse matrix metalloproteinase-9 (MMP-9)
antibody (Abcam, Tokyo, Japan) diluted 1:500 for 60 min and
a fluorescent conjugated goat anti rabbit IgG antibody (Invitro-
gen, Tokyo, Japan) diluted 1:1000 for 45 min at room
temperature. After nuclei were counterstained with Hoechst
33258 (Invitrogen, Tokyo, Japan), fluorescence was visualized
and photographed with a confocal laser scanning microscope FV-
300 with a fluoview software version 4.3 (Olympus, Tokyo,
Japan).
Animal model and drug administration
After induction of anesthesia by intraperitoneal injection of
pentobarbital (50 mg/kg), mice were put on a heated pad and
artificially ventilated (5% carbon dioxide and 95% oxygen) with a
volume-controlled MiniVent Model 845 Ventilator for mice
(Harvard Apparatus, MA, USA) with a stroke volume of 300 mL
and a respiratory rate of 130 breaths/min. Under a surgical
microscope (Leica M6541, Leica Microsystems, Tokyo, Japan), a
left-side thoracotomy was performed and a pericardium was
partially stripped to expose the heart. The left anterior descending
coronary artery was ligated with an 8-0 silk suture (Akiyama
MEDICAL MFG, Tokyo, Japan). Myocardial ischemia was
confirmed by blanching of the anterior wall of the left ventricle
and ST segment elevation on the electrocardiogram. In sham-
operated mice, the same surgical procedures were performed
except for the ligation of the coronary artery. After the chest was
closed with a 5-0 polyester suture (Bear Medic, Tokyo, Japan),
animals were kept warm under a heat lamp during the recovery
period. Infarcted mice were randomly divided into untreated and
donepezil-treated groups. Donepezil was administrated orally at
dosage of 5.0 mg/kg/day. Mice recovered from the surgical
damage were housed under identical conditions within 6 hrs after
surgery and given food and water or drug ad libitum. The cages
were inspected daily for morbidity and mortality, and autopsy was
immediately performed to determine the cause of death in all dead
animals. Cardiac rupture was confirmed based on a diagnosis of
the presence of a large amount of blood clot within the chest cavity
or the wall perforation at the left ventricular infarct area, and a
rupture rate was calculated in percentage as a number of ruptured
animals divided by a number of total operated animals in each
group.
Heart rate and blood pressure measurement
At 3 days after surgery, sham-operated and infarcted mice
were kept in a preheated dark chamber for at least 10 min in
order to increase blood flow to the tail. The mouse tail was
inserted through an appropriate cuff, and heart rate (HR) and
systolic blood pressure (SBP) were measured noninvasively by a
computer-automated tail-cuff system with a data analysis
software (BP-98A, Softron, Tokyo, Japan) according to the
manufacturer’s instructions. HR and SBP were finally deter-
mined by averaging the data obtained from 5 to 10 successful
measurement cycles.
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Mice were anesthetized and sacrificed at appropriate time
points after surgery. Hearts were immediately excised and washed
with ice-cold PBS. Paraformaldehyde-fixed and paraffin-embed-
ded heart samples were sectioned transversely at 3–5 mm thick at a
middle part of the left ventricular infarct area. After dewaxed and
rehydrated by sequential treatment with xylene and a graded
ethanol series, sections were routinely stained with hematoxylin
and eosin (HE) or Masson’s trichrome staining. Histological
images were captured with a digital camera and wall thickness was
measured. Infarct size was calculated in percentage as total infarct
circumference divided by total LV circumference according to the
method of Pfeffer [31,32]. Under high power field magnification
(6400), the number of nuclei at the border zone of the infarct was
manually counted from randomly selected areas (4 areas/section),
and expressed as nuclei per square millimeter. For immunohisto-
chemistry, deparaffinized and rehydrated sections were heated at
95uC for 30 min in a Tris-EDTA buffer (Target Retrieval
Solution, pH 9, DakoCytomation, Denmark) for antigen retrieval.
After a 45 min blocking step with 10% goat serum in TBS-T,
sections were incubated with a rabbit polyclonal anti mouse
MMP-9 antibody (Abcam, Tokyo, Japan) diluted 1:100 for 90 min
and a fluorescent conjugated goat anti rabbit IgG antibody
(Invitrogen, Tokyo, Japan) diluted 1:500 for 45 min at room
temperature. Sections were counterstained for nuclei with Hoechst
33258 (Invitrogen, Tokyo, Japan). Observations were made with a
confocal laser scanning microscope FV-300 (Olympus, Tokyo,
Japan).
RT-PCR
From excised hearts, right ventricle and left ventricle including
septum were dissected. The left ventricle of the infarcted heart was
further separated into infarct and non-infarct area. Infarct tissues
were frozen with liquid nitrogen and stored at 280uC until use.
Total RNA was isolated from tissues by phenol/chloroform
extraction method using TRIzol Reagent (Invitrogen Japan,
Tokyo, Japan) according to the manufacturer’s instructions. The
Reverse Transcriptase XL for RT-PCR kit (Takara, Japan) was
used to obtain first-strand cDNA, which was then amplified with
gene specific primers by a PCR thermal cycler (TP-600, Takara,
Japan). For mouse MMP-9, a sense primer (59-GCATACTTG-
TACCGCTATGG-39) and an antisense primer (59-TAACCG-
GAGGTGCAAACTGG-39) were used. Products were electro-
phoretically fractionated on 2% agarose gels and photographed by
Kodak Gel Logic 100 Imaging System and Kodak Molecular
Imaging Software v. 4. 5. 0.
Electrophoresis and immunoblotting
The left ventricular infarct area was carefully dissected from an
excised heart under a surgical microscope and homogenized in an
extraction buffer containing 50 mM Tris-HCl (pH 6.8), 150 mM
NaCl, 1% Triton X-100 and 10% SDS. After centrifugation, the
supernatants were mixed with same amount of twice concentrated
sample buffer and boiled for 5 min. Protein samples obtained from
in vivo and in vitro studies were separated by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) according to the method of
Laemmli [33]. For immunoblotting analysis, proteins were
electrophoretically transferred to a PVDF-membrane (Immobi-
lon-P, Millipore Japan, Tokyo, Japan) and blocked in a blocking
buffer containing 5% dehydrated skim milk (Difco Laboratories
Inc., MI, USA) for at least 30 min at room temperature or
overnight at 4uC. The membrane was incubated with a rabbit anti
mouse MMP-9 antibody (Abcam, Tokyo, Japan) diluted 1:2000
for 90 min, followed by incubation with a horseradish peroxidase
(HRP)-conjugated goat anti rabbit IgG antibody (Invitrogen,
Tokyo, Japan) diluted 1:5000 for 45 min at room temperature.
HRP activity was detected by chemiluminescence using an ECL
plus Western Blotting Detection System (GE Healthcare Japan
Corporation, Tokyo, Japan).
Gelatin zymography
The enzymatic activity of MMP-9 was measured by gelatin
zymography under nonreducing conditions according to the
standard procedures. Briefly, macrophage culture media or tissue
lysate of left ventricular infarct area were mixed with same amount
of twice concentrated sample buffer which does not contain 2-
mercaptoethanol, and stored at 4uC for overnight without boiling.
The samples were then electrophoretically separated on a
polyacrylamide gel containing 1 mg/ml gelatin as a substrate.
The gel was washed with 2.5% Triton X-100 solution for 60 min
at room temperature, and then incubated with a developing buffer
containing 50 mM Tris-HCl (pH 7.5), 200 mM NaCl, 10 mM
CaCl2,1mM ZnCl2 and 0.02% NaN3 for 20 hrs at 37uC. The gel
was stained with 0.5% Coomassie Brilliant Blue R-250 for 30 min
and destained for appropriate time until clear bands were
visualized, and was scanned by a digital scanner (ES-2000, Epson
Co., Tokyo, Japan).
Statistical analysis
Data are presented either as means 6 SD or a percentage
compared with a control. Nonparametric comparisons between
two groups were performed with a Mann-Whitney U-test.
Multiple comparisons among groups were performed with a
nonparametric one-way ANOVA using a Kruskal-Wallis test. The
mortality data were analyzed by a Chi-square test. A value of
P,0.05 was considered statistically significant.
Results
Effect of donepezil on macrophage MMP-9
Compared to the control (control, 100.0067.08%, n=11),
lipopolysaccaride (LPS) treatment at a concentration of 10 ng/ml
for 3 hrs significantly increased macrophage matrix metallopro-
teinase-9 (MMP-9) secretion to culture medium (LPS, 116.166
5.37% versus control, n=11, P,0.01). However, MMP-9 in
culture medium of the donepezil-pretreated macrophages was
significantly lower than the control (DPZ/LPS, 76.90610.92%
versus control, n=11, P,0.01). Consequently, donepezil pre-
treatment reduced the LPS-induced MMP-9 secretion from
macrophages by 33.80% (P,0.01, Figure 1). In this study, we
used donepezil expecting its inhibitory action on acetylcholines-
terase. Therefore, the effect of ACh on macrophage MMP-9 was
also investigated. However, unexpectedly, the LPS-induced
increase of MMP-9 was not inhibited by pretreatment of ACh
(100 mM) (ACh/LPS in Figure 2a). Moreover, the MMP-9
inhibition by donepezil was observed even in the presence of a
muscarinic ACh receptor blocker, atropine (100 mM) or a
nicotinic ACh receptor blocker, mecamylamine (5 mM) (Atr/
DPZ/LPS and Mec/DPZ/LPS in Figure 2b). These results
indicate that the inhibitory effect of donepezil on macrophage
MMP-9 is independent of ACh. The alteration of MMP-9
content within cells before and after LPS treatment with or
without donepezil pretreatment was examined (Figure 3a). In the
control (control), MMP-9 was stored within cells and also secreted
to culture medium (cell, 52.564 . 7i na . u . ,n = 6a n dm e d i u m ,
48.5615.5 in a.u., n=6). When cells were treated with LPS for
3 hrs (LPS), MMP-9 was significantly decreased in cells
(23.663.8 in a.u., n=6, P,0.01 versus control) and increased
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control), indicating that LPS treatment induced secretion of
MMP-9 from cells to culture medium. In the case of cells
pretreated with donepezil (DPZ/LPS), intracellular MMP-9 was
undetectable levels like that in donepezil-pretreated culture
medium (cell, 29.161.9 in a.u., n=6, P,0.01 versus control,
P,0.01 versus LPS and medium, 34.4610.5 in a.u., n=6,
P,0.05 versus control, P,0.01 versus LPS). It was also observed
that donepezil pretreatment reduced MMP-9 content within cells
not treated with LPS (data not shown). These results indicate that
donepezil suppresses the de novo synthesis of MMP-9 during the
pretreatment period, resulted in the lower content of MMP-9 in
the culture medium even after the LPS treatment. Gelatin
zymography was carried out to analyze the enzymatic activity of
MMP-9 secreted to culture medium (Figure 3b). Although pro-
and active-forms of MMP-9 could not be clearly distinguished,
MMP-9 retained its proteinase activity even after being secreted
to culture medium. The signal intensity of MMP-9 was
significantly high in LPS-treated cells (LPS, 119.33610.73%
versus control, n=6, P,0.01) and low in donepezil-pretreated
and LPS-treated cells (DPZ/LPS, 83.5262.59% versus control,
n=6, P,0.01), compared to control (control, 100.00614.3%,
n=6).
The effect of donepezil on the macrophage MMP-9 was further
examined by immunocytochemistry (Figure 4). Isolated and
cultured macrophages were observed to attach well to a
substratum and form widespreading pseudopodia. Compared to
the control that showed a high proportion of cells with spindle
shapes (Figure 4a), LPS-treated cells displayed a relatively round
shape and a numerous intracellular vacuoles (Figure 4c). Such
morphological alterations induced by LPS treatment were also
observed in donepezil-pretreated cells (Figure 4e), indicating that
the donepezil pretreatment had no effect on the macrophage
reactivity to LPS treatment. Immunofluorescence microscopy with
anti MMP-9 antibody showed that MMP-9 was distributed
around cytoplasm in control and LPS-treated cells (Figures 4b
and d), whereas donepezil decreased the immunoreactivities of
MMP-9 within cytoplasm (Figure 4f). These results indicate that
the donepezil pretreatment decreased MMP-9 content within the
cell, which coincided with the results obtained immunoblot
analysis shown in Figure 3a.
Effect of donepezil on risk of cardiac rupture after
myocardial infarction
A total of 330 mice was operated (310 mice were subjected to
coronary artery ligation, whereas 20 mice underwent sham
operation) and 60 mice (18.2%) died within 24 hrs due to surgical
reasons. No deaths were observed in the sham-operated mice. Ten
mice (3.7%) that died during the follow up period (4 days
postinfarction) without diagnosis of cardiac rupture and 37 mice
(13.7%) that had obviously small left ventricular infarction were
excluded from the study. Consequently, 223 mice were allocated
into examining an incidence of rupture, heart rate (HR) and
systolic blood pressure (SBP) measurement, histology, immuno-
histochemistry, and tissue collection for RT-PCR, Western blot
analysis and gelatin zymography. Surviving mice with myocardial
infarction (MI) were divided into 2 groups; untreated and
donepezil-treated (DPZ) groups.
HR and SBP were measured noninvasively using a computer-
automated tail-cuff system in sham-operated and infarcted mice at
day 3 after surgery. As shown in Table 1, there was no significant
difference in HR among all groups of mice (sham, 493670 bpm,
n=6; untreated, 548653 bpm, n=9 and DPZ, 528643 bpm,
n=9, N.S.). On the other hand, SBP was decreased significantly in
infarcted groups (untreated, 81.667.4 mmHg, n=9, P,0.01 and
DPZ, 78.367.9 mmHg, n=9, P,0.01) compared with the sham
group (98.965.0 mmHg, n=6), indicating a progression of
cardiac dysfunction after MI. However, values of the decreased
SBP in the infarcted groups were comparable. In another set of
experiments showed that no significant differences in HR and SBP
were observed in normal mice treated with donepezil (DPZ,
5.0 mg/kg/day) for 3 days (HR, 504636 bpm, n=6 and SBP,
103.769.8 mmHg, n=6). These results indicate that the done-
pezil administration at the dosage of 5.0 mg/kg/day did not affect
HR and SBP in normal and infarcted mice. When mice were
sacrificed at 3 days after MI, all excised hearts were weighed. The
ratio of heart weight to body weight (HW/BW) was significantly
increased in infarcted groups (untreated, 5.8560.66 mg/g, n=11,
P,0.01 and DPZ, 5.6060.39 mg/g, n=11, P,0.01) compared
with the sham group (4.3160.25 mg/g, n=7). However, no
significant difference was found in HW/BW among infarcted
groups, suggesting that donepezil has no effect on the postinfarct
cardiac enlargement during the acute phase of MI (Table 1).
Histological analysis was performed on HE stained heart
sections at 3 days after MI (Table 2). Although wall thickness of
left ventricle and septum were not significantly different between
untreated and donepezil-treated groups, the ratio of these in the
donepezil-treated group was significantly greater than that in the
untreated group (untreated, 0.5160.07, n=5 and DPZ,
0.6960.20, n=5, P,0.05). On the contrary, right ventricular
wall thickness in the donepezil-treated group was significantly
thinner than that of the untreated group (untreated,
56.168.91 mm, n=5 and DPZ, 43.967.31 mm, n=5, P,0.05).
Infarct size was comparable between two groups. In the heart
sections at 3 days after MI, it was observed that cardiac myocytes
at mid-infarct area became necrotic and a large number of
inflammatory cells infiltrated into infarct border zone. Under high
power field magnification, nuclear density at the border zone of
the infarct was counted and was significantly low in the donepezil-
treated group compared to the untreated group (untreated,
4.4260.36610
3/mm
2, n=5 and DPZ, 3.5060.29610
3/mm
2,
n=5,P,0.01).
Within 2 days after surgery, no mice were dead in all groups.
Thereafter, infarcted mice began to die due to cardiac rupture at
day 3 and the numbers of those mice were further increased at day
4 after MI. As described in Methods, all dead mice were
immediately autopsied to determine the cause of death, and
cardiac rupture was confirmed based on a diagnosis of the
presence of a large amount of blood clot within the chest cavity
(Figure 5a) or a wall perforation at a left ventricular infarct area
(Figures 5b and c). The wall perforation tended to occur more
frequently in a central region of an infarcted left ventricle or a
border zone between infarcted and non-infarcted myocardium,
where wall strength became relatively weak (Figure 5d). At both 3
and 4 days after MI, a greater number of animals died with
rupture in the untreated group than in the donepezil-treated
group, and the rupture rate of the untreated group was reached to
30.6%, whereas the donepezil-treated group showed a lower
incidence of rupture (8.7%). Statistical analysis showed that,
despite the comparable values of HR and SBP at day 3 after MI
among infarcted groups, donepezil administration to infarcted
mice significantly decreased the incidence of rupture during the
acute phase of MI (P,0.01, Table 3).
Effect of donepezil on MMP-9 in left ventricular infarct
area
As shown in Figure 6, immunofluorescence microscopy revealed
that MMP-9 signals were localized at a region of an infarct left
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myocardium where a large number of nuclei were observed,
suggesting that MMP-9 was produced by inflammatory cells
including macrophages which infiltrated into infarct area after MI.
Therefore, the effect of donepezil on the MMP-9 expression in
tissues of left ventricular infarct area was examined at 3 days after
MI. RT-PCR analysis showed that MMP-9 mRNA level was
significantly increased (untreated, 532.606119.24%, n=11,
P,0.01) compared with sham group (100.00630.00%, n=6),
and that the increase of MMP-9 mRNA level was significantly
attenuated in the donepezil-treated group (DPZ, 306.00686.52%,
n=11, P,0.01) compared with the untreated group (Figure 7a).
At the same time point, Western blot analysis showed that MMP-9
protein level was significantly increased in infarcted groups
(untreated, 562.68623.11%, n=5, P,0.01 and DPZ, 525.756
16.31%, n=5, P,0.01) compared with sham group (100.006
23.11%, n=3), and was slightly but significantly decreased in the
donepezil-treated group compared with the untreated group
(P,0.05, Figure 7b). Enzymatic activity of MMP-9 in the left
ventricular infarct area was evaluated by gelatin zymography at 3
days after MI (Figures 7c and d). Compared to the untreated
group (untreated), signal intensity in both pro- and active-forms of
MMP-9 in the donepezil-treated group (DPZ) were significantly
reduced (pro MMP-9; untreated, 85.467.3 in a.u., n=7 and DPZ,
74.566.9 in a.u., n=7, P,0.01, active MMP-9; untreated,
27.764.5 in a.u., n=7 and DPZ, 16.761.9 in a.u., n=7,
P,0.01, Figure 7c). Furthermore, relative enzymatic activity of
MMP-9 was expressed as the ratio of active-form to total (pro- +
active-form) MMP-9 signal intensity, and was significantly
decreased in the donepezil-treated group compared to the
untreated group (untreated, 0.2460.02, n=7 and DPZ,
0.1860.01, n=7, P,0.01, Figure 7d).
Discussion
Since we reported that the chronic vagal stimulation markedly
improved the cardiac function and decreased mortality in a post-
ischemic rat model of heart failure [3], we have focusing on
elucidating the cellular and molecular mechanisms behind the
ACh-induced cardioprotection. As results, vagal stimulation and
Figure 1. Effect of donepezil on MMP-9 in macrophages. MMP-9 in culture medium was evaluated by Western blot analysis before and after
LPS (10 ng/ml) treatment with or without donepezil pretreatment (100 mM). Compared to control (control), LPS treatment significantly increased
MMP-9 in culture medium (LPS), whereas donepezil pretreatment significantly decreased MMP-9 even in the presence of LPS (DPZ/LPS). #, P,0.01.
doi:10.1371/journal.pone.0020629.g001
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in culture medium, which was inhibited by donepezil pretreatment (DPZ/LPS). However, ACh could not reproduce the inhibitory effect of donepezil
(ACh/LPS). (b) Donepezil inhibited the LPS-induced MMP-9 even in the presence of a muscarinic ACh receptor blocker, atropine (Atr/DPZ/LPS), or a
nicotinic ACh receptor blocker, mecamylamine (Mec/DPZ/LPS). Both blockers showed no effect on LPS-induced MMP-9 independently (Atr/LPS and
Mec/LPS).
doi:10.1371/journal.pone.0020629.g002
Figure 3. Western blot and zymographic analysis on macrophage MMP-9. (a) Western blot analysis of MMP-9 content in culture media and
macrophage cells before and after LPS treatment with or without donepezil pretreatment. In control (control), MMP-9 was stored within cells and also
secreted to culture medium. In LPS-treated cells (LPS), MMP-9 was significantly decreased within cells and increased in culture medium. In donepezil-
pretreated and LPS-treated cells (DPZ/LPS), MMP-9 within both cells and medium were as low as undetectable level. The expression of a-tubulin was
shown as an internal control. #, P,0.01 versus control. ##, P,0.01 versus LPS. *, P,0.05 versus control. (b) Gelatin zymography for analysis of MMP-
9 enzymatic activity. Compared to control (control), proteinase activity of MMP-9 secreted to culture medium was significantly high in LPS-treated
cells (LPS) and low in donepezil-pretreated and LPS-treated cells (DPZ/LPS). #, P,0.01.
doi:10.1371/journal.pone.0020629.g003
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junction channels and protect hearts against ischemia-induced
lethal arrhythmias [4], 2) protect cardiomyocytes against hypoxia
through the PI3K/Akt/HIF-1a pathway [5], 3) keep cell-cell
communication by preserving the gap-junction protein level
during hypoxia through inhibition of the connexin 43 degradation
pathway [34], and 4) prevent a reperfusion-induced collapse in
mitochondrial transmembrane potential by inhibition of mito-
chondrial permeability transition pore opening [35]. In the present
study, to test whether or not an acetylcholinesterase inhibitor
donepezil reproduced the cardioprotective effect of the vagal
stimulation or ACh, we investigated the effect of donepezil on
Figure 4. Immunocytochemistry with anti MMP-9 antibody in macrophages. DIC images showed that control macrophages had a spindle
shape (a), whereas LPS-treated macrophages had a relatively round shape and numerous intracellular vacuoles regardless of donepezil pretreatment
(c and e). Immunofluorescence micrographs showed that MMP-9 signals were observed around cytoplasm in the control (b) and the LPS-treated cells
(d), which was lowered to undetectable levels by donepezil pretreatment (f).
doi:10.1371/journal.pone.0020629.g004
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shown that donepezil inhibits macrophage MMP-9 and reduces
the risk of cardiac rupture during the acute phase of MI. These
findings, taken together with our earlier studies [13–15], indicate
that donepezil would be a novel pharmacotherapeutic drug for
heart failure patients.
Murine MI is a good model for exploration of the molecular
processes of ischemia-induced tissue injury, because the post-
infarct inflammatory response shares common characteristics
with higher mammalian species [36] and the murine ventricular
free wall often ruptures within a week after the onset of MI, like
humans [24,37,38]. The postinfarct inflammation has been
recognized as an important feature of the cardiac remodeling
after MI. A number of studies have reported that MMPs play
important roles in the left ventricular remodeling, and inhibiting
the enzymatic activity of MMPs prevented the progress of cardiac
dysfunction and improved survival following MI [26,29,39].
Among the members of MMP family, MMP-9 seems to be a key
enzyme in early myocardial remodeling and fatal cardiac rupture
during an acute phase of MI [25,27]. After the onset of MI,
macrophage infiltrates into infarcted myocardium and expresses
MMP-9 to degrade extracellular matrix [40,41]. The present
study demonstrated that, in in vitro study, donepezil inhibited
MMP-9 in LPS-treated macrophages (Figures 1, 2, 3, 4) and that,
in in vivo study, donepezil attenuated the inflammatory cell
infiltration into the infarcted myocardium and decreased the
expression and the enzymatic activity of MMP-9 at the infarct
area (Figure 7), thereby reduced the risk of cardiac rupture during
the acute phase of MI (Table 3). These results indicate that
donepezil is a possible candidate agent for affecting the
postinfarct inflammation and the extracellular matrix remodeling.
Macrophage MMP-9 in culture medium was not affected by
coincubation with donepezil (100 mM) at 37uC for 3 hrs (data not
shown), suggesting that donepezil might not possess degradation
activity toward MMP-9 but attenuate macrophage MMP-9
protein expression through certain receptors not yet identified.
To clarify a donepezil-binding receptor and an intracellular
signaling pathway downstream of the receptor, a future study
should be conducted.
Histological analysis on infarcted heart sections showed that left
ventricular wall thinning and right ventricular hypertrophy were
attenuated in the donepezil-treated group (Table 2), however,
without significant differences of the heart to body weight ratio
and the infarct size, suggesting that donepezil seems to have a mild
anti-remodeling effect on the infarcted heart at this time point (3
days postinfarction). Masson’s trichrome staining on the hearts 3
days after MI also supported this result, because collagen fibers
were not distributed and cardiac myocytes still existed throughout
the infarct area (data not shown). These observations indicate that
the extracellular matrix turnover, i.e., the synthesis and degrada-
tion of collagen, to replace necrotic cardiomyocytes has not yet
occurred, and LV remodeling would progress later. Nevertheless,
in this study, cardiac rupture occurred frequently within 4 days
after the onset of MI, and donepezil treatment reduced the risk of
the lethal event. When ruptured, the wall perforation tended to
occur at the infarct border zone (Figures 5c and d) where a large
number of inflammatory cells invaded (Figure 6b). The number of
inflammatory cells at the area was significantly lower in the
donepezil-treated group than the untreated group (Table 2),
indicating that donepezil attenuated the infiltration of the
inflammatory cells into the infarct border zone after MI. Although
it is still unclear whether or not donepezil inhibited MMP-9
production of the infiltrated inflammatory cells at the infarct
border zone, it is conceivable that donepezil exerted the anti-
rupture effect by inhibiting the inflammatory cell infiltration at the
infarct border zone and possibly by retaining the local strength of
the infarct ventricular wall.
In this study, the expression of MMP-9 mRNA in the left
ventricular infarct area at 3 days after MI was reduced by
donepezil in approximately half compared with that in the
untreated group, whereas this was not accurately reflected in the
protein level at this time point (Figures 7a and b). This might be
due to the time difference in the process of transcription to
translation, i.e., the inhibitory effect of donepezil on the de novo
synthesis of MMP-9. In any case, the donepezil-treated mice
showed a significantly lower incidence of cardiac rupture than the
untreated mice (Table 3), accompanied by a reduced expression
and enzymatic activity of MMP-9 in the left ventricular infarct
area (Figure 7). Further studies are required to elucidate whether
or not donepezil has effect on other types of MMP family members
such as MMP-2 and MMP-13, and on their endogenous
inhibitors, tissue inhibitor of matrix metalloproteinases (TIMPs).
The effects of donepezil on the other cells including neutrophils,
another source of MMP-9 [42], and cardiomyocytes should also be
investigated.
Chronic effect of donepezil on ischemic heart failure has
been also investigated in rats, demonstrating that donepezil
improved the long-term survival through the prevention of
postinfarct ventricular dysfunction and cardiac remodeling
[13,43,44]. Although cardiac rupture has not so far been
reported in rat models with MI as well as other laboratory
Table 1. Physiological characteristics in sham operated and
infarcted mice at 3 days after MI.
sham infarcted
untreated DPZ
n6 9 9
HR (bpm) 493670 548653 528643
SBP (mmHg) 98.965.0 81.667.4 # 78.367.9 #
n7 1 1 1 1
HW/BW (mg/g) 4.3160.25 5.8560.66 # 5.6060.39 #
Values are means 6 SD. HR, heart rate; SBP, systolic blood pressure; HW/BW,
heart weight to body weight ratio; DPZ, donepezil-treated group. #, P,0.01
versus sham group.
doi:10.1371/journal.pone.0020629.t001
Table 2. Histological analysis in heart sections at 3 days after
MI.
untreated DPZ
n5 5
Wall thickness left ventricle (mm) 68.7610.7 89.8621.5
septum (mm) 134.6613.1 132.066.2
left ventricle/septum 0.5160.07 0.6960.20 ##
right ventricle (mm) 56.168.91 43.967.31 ##
Infarct size (%) 68.363.12 62.669.61
Nuclear density
(610
3/mm
2)
4.4260.36 3.5060.29 #
Values are means 6 SD. DPZ, donepezil-treated group. #, P,0.01. ##, P,0.05.
doi:10.1371/journal.pone.0020629.t002
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cological intervention of the MMPs attenuates the postinfarct
remodeling [26,28,46,47]. Furthermore, donepezil pretreat-
ment (100 mM) inhibited the LPS-induced increase of MMP-9
secretion even in rats macrophage (data not shown). Therefore,
the inhibitory effect of donepezil on macrophage MMP-9 is
also involved in protecting from rat cardiac remodeling during
the acute phase of MI. Studies to determine the long-term
effects of donepezil on inflammatory responses after MI are
also needed.
It is well known that a large dose of donepezil has a heart-
rate slowing effect [48]. The dose of donepezil administrated to
mice in the present study was approximately 50 times larger
than the therapeutic doses used for Alzheimer’s disease patients
in clinical setting. However, the selected doses of donepezil
lowered an incidence of cardiac rupture during acute phase of
MI without slowing heart rate, indicating that the anti-rupture
effect of donepezil was not brought by its bradycardiac action.
Although the daily dose at 5.0 mg/kg has been extensively used
in animal study with donepezil, it should be considered
whether or not the clinical dose for donepezil also has a
beneficial effect on heart failure comparably with the higher
dose. It was shown that the oral administration of donepezil at
dose of 0.5 mg/kg/day prevented the progression of left
ventricular dysfunction on rat MI heart (unpublished data),
Figure 5. Light micrographs of an autopsied mouse that died due to cardiac rupture. (a) An infarcted mouse after the incidence of cardiac
rupture. The chest cavity was filled with a large amount of clotted blood surrounding the heart. (b) The heart excised from the mouse. The ischemic
area was visually identified by the pale myocardium. A white arrowhead represents the position of the coronary artery ligation. (c) An enlarged
micrograph of the area shown by the small rectangle with a broken line in (b). A left ventricular perforation tends to occur at the border zone
between infarcted and non-infarcted myocardium (black arrowheads). (d) The ruptured heart sectioned at a middle part of the left ventricular infarct
area. The tissue was stained with hematoxylin and eosin. A black arrowhead shows the position of wall perforation occurred at left ventricular infarct
border zone. RV, right ventricle; LV, left ventricle; IA, infarct area.
doi:10.1371/journal.pone.0020629.g005
Table 3. Cardiac rupture rate at 4 days after MI.
sham infarcted
untreated DPZ
operated 6 49 46
ruptured 0 15 4
rupture rate (%) 0 30.6 8.7 #
DPZ, donepezil-treated group. #, P,0.01 versus untreated group.
doi:10.1371/journal.pone.0020629.t003
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necessarily required for the treatment of heart failure. Actually,
our recent retrospective cohort study showed that donepezil-
treated patients with Alzheimer’s disease had reduced cardio-
vascular mortality [49].
It has been reported that the cholinergic anti-inflammatory
pathway can directly modulate the systemic response through ACh
by attenuating the release of inflammatory cytokines from
macrophages. In the present study, donepezil inhibited MMP-9
expression in LPS-treated macrophages, but not tumor necrosis
factor (TNF). The inhibitory effect of donepezil on macrophage
MMP-9 could not be reproduced by ACh (Figure 2a) or other
kinds of acetylcholinesterase inhibitors such as physostigmine and
galanthamine (data not shown). Experimentally, ACh was shown
to inhibit TNF release from LPS-stimulated macrophages [1],
however, in our study, ACh failed to inhibit TNF release (data not
shown). This discrepancy between our results and those of
Borovikova et al. [1] might be derived from different cell sources
and culture conditions. Moreover, neither a muscarinic ACh
receptor blocker, atropine, nor a nicotinic ACh receptor blocker,
mecamylamine, attenuated the inhibitory effect of donepezil on
the MMP-9 release (Figure 2b). These results indicate that the
specific characteristics of donepezil would be independent of its
acetylcholinesterase inhibition. Recently accumulating evidence
strongly suggests that donepezil possesses a direct cytoprotective
activity, independent of its acetylcholinesterase-inhibitory mecha-
nism [12,50–52]. Our previous study using an ischemic hindlimb
model of a7 nicotinic receptor-deleted mice demonstrated the
beneficial effect of donepezil on acceleration of angiogenesis,
suggesting that donepezil rather exerts its specific effect indepen-
dent of a7 nicotinic receptors [15]. Further studies focusing on the
pharmacological properties of donepezil which directly affect cells
via mechanism other than acetylcholinesterase inhibitory action
are needed.
In summary, the results of the study reported here suggest that
donepezil inhibits MMP-9 in macrophages which infiltrate into the
infarcted myocardium, thereby contributes at least in part to the
reduction of the risk in left ventricular free wall rupture during the
acute phase of MI. Although donepezil is clinically used as a
central type inhibitor of neural acetylcholinesterase, the donepezil-
induced cardioprotection observed in this study may not be due to
its pharmacological property of acetylcholinesterase inhibition.
Understanding of the cellular and molecular mechanism of the
donepezil-induced cardioprotection would help to establish a
Figure 6. Immunohistochemistry of MMP-9 in infarcted myocardium. (a) A DIC image of the left ventricular infarct area. (b and c) The same
fields stained with Hoechst 33258 to indicate the position of nuclei (b) and with a rabbit anti mouse MMP-9 antibody to indicate the localization of
MMP-9 (c). (d) A schematic drawing of the field observed. IA and NIA represent infarct and non-infarct area, respectively.
doi:10.1371/journal.pone.0020629.g006
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PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e20629Figure 7. MMP-9 expression and its enzymatic activity in infarcted myocardium. MMP-9 expression in the left ventricular infarct area was
compared among sham, untreated and donepezil-treated groups in mRNA (a) and protein level (b) at 3 days after myocardial infarction. (a) Compared
to sham group (sham), MMP-9 mRNA in infarcted groups was significantly increased (untreated and DPZ). The increase of MMP-9 mRNA was
significantly attenuated in the donepezil-treated group compared to the untreated group. #, P,0.01 versus sham group. ##, P,0.01 versus
untreated group. (b) Compared to sham group (sham), MMP-9 protein in infarcted groups was significantly increased (untreated and DPZ). The
increase of MMP-9 was slightly but significantly attenuated in the donepezil-treated group compared to the untreated group. #, P,0.01 versus sham
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heart failure.
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